BCM
AMAG

Beck Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Beck Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-23,225
Closed -$1.6M – 152
2015
Q2 		$1.6M Buy
+23,225
New +$1.46M 0.86% 41

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Beck Capital Management's AMAG Position: Q3 2015 in Review

Beck Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q3 2015, closing a stake of 23,225 shares — an estimated $1.6M sold.

Beck Capital Management first reported a position in AMAG in Q2 2015 and held it in 1 quarter. The position peaked at $1.6M in Q2 2015. 210 funds tracked by Wall St. Rank hold AMAG as of Q3 2015.

  • Beck Capital Management reported no remaining AMAG Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Beck Capital Management sold 23,225 AMAG Pharmaceuticals shares in Q3 2015, an estimated $1.6M.
  • Beck Capital Management first reported a position in AMAG Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Beck Capital Management's AMAG Pharmaceuticals position peaked at $1.6M in Q2 2015.
  • 210 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2015.

Based on Beck Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.